All participants were screened with the Structured Interview for Prodromal Syndromes and Scale of Prodromal Symptoms (SIPS/SOPS; Miller et al., 2003). The inclusion/exclusion criteria were largely identical to those described by Piskulic et al. (2012) and included: 1) meeting criteria for at least one of three prodromal syndromes using the SIPS/SOPS; 2) no current or lifetime Axis I psychotic disorder; 3) IQ greater than 70 (Wechsler Adult Intelligence Scale [WAIS] or Wechsler Intelligence Scale for Children [WISC] only administered if low IQ suspected); and 4) no current or past CNS disorder (medical or psychiatric) which may account for prodromal symptoms. CHR patients differed highly significantly from healthy controls in all SOPS subscales in the expected direction (cf. Table 1). There were no group × gender interactions or gender main effects for any of the SOPS subscales. Notably, the SOPS negative symptoms were highly comparable to what has been reported for a larger cohort (Piskulic et al., 2012), as deterioration in role function was most prominent (with 81% of the current CHR patients reporting a score of 3 or higher), followed
